Conversion to public limited liability company and name change registered

Lytix Biopharma AS

Oslo, Norway, 16 April 2026: Reference is made to the stock exchange
announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 26
January 2026 regarding the extraordinary general meeting held the same day, at
which it was resolved, inter alia, to convert the Company from a private limited
liability company (AS) to a public limited liability company (ASA).

The conversion and the change of the Company's name to "Lytix Biopharma ASA" has
today been registered with the Norwegian Register of Business Enterprises (Nw.:
Foretaksregisteret).
Disclosure regulation:

This information is subject to a duty of disclosure pursuant to the Company's
continuing obligations as a company listed on Euronext Growth.

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.

More information:
Access the news on Oslo Bors NewsWeb site